







**FIGURE 1****Mean Change From Baseline in LogMAR Visual Acuity Score****(Overall Analysis)**

**FIGURE 2****Preservation of Vision (< 3 logMAR line Decrease) at Month 6****(Overall Analysis)** $p=.0799$  (15 mg vs. Placebo)

**FIGURE 3****Preservation of Vision (< 3 logMAR line Decrease) at Month 6****(Subgroup Analysis of Predominantly Classic Lesions)**

**FIGURE 4****Patients With  $\geq 2$  logMAR Line Improvement in Vision at Month 6****(Overall Analysis)****p=.025 (15 mg vs. Placebo)**

**FIGURE 5****Percent Change from Baseline in Lesion Sizes  
Total Lesion (mm<sup>2</sup>)****CNV Component (mm<sup>2</sup>)****Classic Component (mm<sup>2</sup>)**